A Double-blind, Placebo-controlled, Randomised, Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KBP-089 in Patients With Type II Diabetes
Latest Information Update: 17 Sep 2021
At a glance
- Drugs DACRA 089 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors KeyBioScience
Most Recent Events
- 01 Sep 2020 Status changed from recruiting to discontinued after completion of Cohort 2 for strategic reasons due to limited PD effects
- 10 Apr 2019 New trial record